35 related articles for article (PubMed ID: 22060033)
1. Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect.
Ibrahim TS; Hawwas MM; Malebari AM; Taher ES; Omar AM; Neamatallah T; Abdel-Samii ZK; Safo MK; Elshaier YAMM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):802-818. PubMed ID: 33730937
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR investigation of biphenylaminoquinoline derivatives with benzyloxy substituents as promising anticancer agents.
Wu YC; Lu MT; Kuo SC; Chu PC; Chang CS
Chem Biol Drug Des; 2024 May; 103(5):e14509. PubMed ID: 38684369
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation.
Rilova E; Erdmann A; Gros C; Masson V; Aussagues Y; Poughon-Cassabois V; Rajavelu A; Jeltsch A; Menon Y; Novosad N; Gregoire JM; Vispé S; Schambel P; Ausseil F; Sautel F; Arimondo PB; Cantagrel F
ChemMedChem; 2014 Mar; 9(3):590-601. PubMed ID: 24678024
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anti-breast cancer activities of substituted quinolines.
Shi A; Nguyen TA; Battina SK; Rana S; Takemoto DJ; Chiang PK; Hua DH
Bioorg Med Chem Lett; 2008 Jun; 18(11):3364-8. PubMed ID: 18457950
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.
Herdman CA; Strecker TE; Tanpure RP; Chen Z; Winters A; Gerberich J; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
Medchemcomm; 2016 Dec; 7(12):2418-2427. PubMed ID: 28217276
[TBL] [Abstract][Full Text] [Related]
6. Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing.
Hartmann RW; Fahrner R; Shevshenko D; Fyrknäs M; Larsson R; Lehmann F; Odell LR
ChemMedChem; 2020 Dec; 15(24):2500-2512. PubMed ID: 33063934
[TBL] [Abstract][Full Text] [Related]
7. Advances in antitumor research of CA-4 analogs carrying quinoline scaffold.
Wang C; Chang J; Yang S; Shi L; Zhang Y; Liu W; Meng J; Zeng J; Zhang R; Xing D
Front Chem; 2022; 10():1040333. PubMed ID: 36385996
[TBL] [Abstract][Full Text] [Related]
8. Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents.
Hura N; Sawant AV; Kumari A; Guchhait SK; Panda D
ACS Omega; 2018 Aug; 3(8):9754-9769. PubMed ID: 31459105
[TBL] [Abstract][Full Text] [Related]
9. Drug-Clinical Agent Molecular Hybrid: Synthesis of Diaryl(trifluoromethyl)pyrazoles as Tubulin Targeting Anticancer Agents.
Hura N; Naaz A; Prassanawar SS; Guchhait SK; Panda D
ACS Omega; 2018 Feb; 3(2):1955-1969. PubMed ID: 30023819
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish.
Shi YW; Yuan W; Wang X; Gong J; Zhu SX; Chai LL; Qi JL; Qin YY; Gao Y; Zhou YL; Fan XL; Ji CY; Wu JY; Wang ZW; Liu D
Sci Rep; 2016 Jul; 6():30189. PubMed ID: 27452835
[TBL] [Abstract][Full Text] [Related]
11. Diaryl and heteroaryl sulfides: synthesis via sulfenyl chlorides and evaluation as selective anti-breast-cancer agents.
Yonova IM; Osborne CA; Morrissette NS; Jarvo ER
J Org Chem; 2014 Mar; 79(5):1947-53. PubMed ID: 24564865
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.
Reddy MV; Mallireddigari MR; Pallela VR; Cosenza SC; Billa VK; Akula B; Subbaiah DR; Bharathi EV; Padgaonkar A; Lv H; Gallo JM; Reddy EP
J Med Chem; 2013 Jul; 56(13):5562-86. PubMed ID: 23750455
[TBL] [Abstract][Full Text] [Related]
13. An overview of tubulin inhibitors that interact with the colchicine binding site.
Lu Y; Chen J; Xiao M; Li W; Miller DD
Pharm Res; 2012 Nov; 29(11):2943-71. PubMed ID: 22814904
[TBL] [Abstract][Full Text] [Related]
14. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
Lee HY; Chang JY; Nien CY; Kuo CC; Shih KH; Wu CH; Chang CY; Lai WY; Liou JP
J Med Chem; 2011 Dec; 54(24):8517-25. PubMed ID: 22060033
[TBL] [Abstract][Full Text] [Related]
15. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors.
Nien CY; Chen YC; Kuo CC; Hsieh HP; Chang CY; Wu JS; Wu SY; Liou JP; Chang JY
J Med Chem; 2010 Mar; 53(5):2309-13. PubMed ID: 20148562
[TBL] [Abstract][Full Text] [Related]
16. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
Chang JY; Yang MF; Chang CY; Chen CM; Kuo CC; Liou JP
J Med Chem; 2006 Oct; 49(21):6412-5. PubMed ID: 17034147
[TBL] [Abstract][Full Text] [Related]
17. 4- and 5-aroylindoles as novel classes of potent antitubulin agents.
Liou JP; Wu CY; Hsieh HP; Chang CY; Chen CM; Kuo CC; Chang JY
J Med Chem; 2007 Sep; 50(18):4548-52. PubMed ID: 17685504
[TBL] [Abstract][Full Text] [Related]
18. Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents.
Hamze A; Alami M; Provot O
Eur J Med Chem; 2020 Mar; 190():112110. PubMed ID: 32061961
[TBL] [Abstract][Full Text] [Related]
19. Combretastatins: more than just vascular targeting agents?
Greene LM; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2015 Nov; 355(2):212-27. PubMed ID: 26354991
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
